Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy
Stacey Schultz‐Cherry, Maureen A. McGargill, Paul G. Thomas, Jeremie H. Estepp, Aditya H. Gaur, E. Kaitlynn Allen, Kim Allison, Li Tang, Richard J. Webby, Sean Cherry, Chun-Yang Lin, Thomas Fabrizio, Elaine Tuomanen, Joshua Wolf, SJTRC Investigative Team, Ericka Kirkpatrick Roubidoux, Pamela Freiden, Tomi Mori, Diego R. Hijano, Hana Hakim, David C. Brice, Ashley Castellaw, Florian Krammer, David E. Wittman, Jason Hodges, Ronald H. Dallas, Valerie Cortez, Ana Vazquez-Pagan, Resha Bajracharya, Brandi L. Clark, Lee-Ann Van de Velde, Walid Awad, Taylor L. Wilson, Allison M. Kirk, Randall T. Hayden, James E. Hoffman, Jamie Russell-Bell, James Sparks
Abstract
The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and "antibody interference" might hinder immune responses leading to vaccine failure. In an institutional review board-approved prospective study, we found that an individual who received mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar postvaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD) for 4 important SARS-CoV-2 variants (B.1, B.1.1.7, B.1.351, and P.1) as other participants who were also vaccinated following COVID-19. Vaccination against COVID-19 shortly after COVID-19-specific monoclonal antibody can boost and expand antibody protection, questioning the need to delay vaccination in this setting. TRIAL REGISTRATION: The St. Jude Tracking of Viral and Host Factors Associated with COVID-19 study; NCT04362995; https://clinicaltrials.gov/ct2/show/NCT04362995.